Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
40
CATX Quote, Financials, Valuation and Earnings
Last price:
$2.4000
Seasonality move
:
21.96%
Day range:
$2.1700 - $2.4100
52-week range:
$1.6000 - $5.3881
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
162.05x
P/B ratio:
0.73x
Volume:
1.9M
Avg. volume:
1.8M
1-year change:
-35.58%
Market cap:
$177.7M
Revenue:
$1.5M
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingPerspective Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.3077, Perspective Therapeutics, Inc. has an estimated upside of 414.97% from its current price of $2.3900.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.0000 representing -67.36% downside risk from its current price of $2.3900.
Fair Value
-
According to the consensus of 13 analysts, Perspective Therapeutics, Inc. has 414.97% upside to fair value with a price target of $12.3077 per share.
CATX vs. S&P 500
-
Over the past 5 trading days, Perspective Therapeutics, Inc. has overperformed the S&P 500 by 7.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Perspective Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Perspective Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Perspective Therapeutics, Inc. reported revenues of $209K.
Earnings Growth
-
Perspective Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Perspective Therapeutics, Inc. reported earnings per share of -$0.35.
Enterprise value:
6.8M
EV / Invested capital:
0.03x
Price / LTM sales:
162.05x
EV / EBIT:
--
EV / Revenue:
6.37x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.9M
Return On Assets:
-31.7%
Net Income Margin (TTM):
-9884.19%
Return On Equity:
-37.63%
Return On Invested Capital:
-37.13%
Operating Margin:
-13330.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.6M | $1.5M | $1.1M | $369K | $209K | |
| Gross Profit | $1.4M | -$310K | -$1.9M | -$300K | -$566K | |
| Operating Income | -$31.4M | -$55.7M | -$94.6M | -$18.6M | -$27.9M | |
| EBITDA | -$30.6M | -$53.8M | -$91.7M | -$18M | -$27.1M | |
| Diluted EPS | -$0.93 | -$1.01 | -$1.46 | -$0.21 | -$0.35 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65M | $57.5M | $21.7M | $270.2M | $178.5M | |
| Total Assets | $68.7M | $62.5M | $110.5M | $391.2M | $294.8M | |
| Current Liabilities | $1.8M | $4M | $8.1M | $28.1M | $20.6M | |
| Total Liabilities | $3M | $4.8M | $11.7M | $62.7M | $52.6M | |
| Total Equity | $65.8M | $57.7M | $98.8M | $328.5M | $242.2M | |
| Total Debt | $459K | -- | $3M | $3.4M | $2.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.8M | -- | -$84.4M | $3.4M | -$16.3M | |
| Cash From Investing | $24.3M | -- | -$125.9M | -$29.7M | $14M | |
| Cash From Financing | $433K | -- | $10.7M | $628K | $213K | |
| Free Cash Flow | -$31.9M | -- | -$106.9M | -$26.4M | -$18.3M | |
CATX
Sector
Market Cap
$177.7M
$28.4M
Price % of 52-Week High
44.36%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-4.16%
-1.32%
1-Year Price Total Return
-35.58%
-22.19%
Beta (5-Year)
1.222
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.2225
200-day SMA
Sell
Level
$3.0122
Bollinger Bands (100)
Sell
Level
2.5666 - 4.0466
Chaikin Money Flow
Sell
Level
-71.5M
20-day SMA
Buy
Level
$2.1955
Relative Strength Index (RSI14)
Sell
Level
48.6244
ADX Line
Sell
Level
24.7526
Williams %R
Neutral
Level
-25.641
50-day SMA
Sell
Level
$2.9568
MACD (12, 26)
Sell
Level
-0.1751
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
70.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4535)
Sell
CA Score
(Annual)
Level (-0.4007)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.1808)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Stock Forecast FAQ
In the current month, CATX has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $12.3077.
-
Where Will Perspective Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Perspective Therapeutics, Inc. share price will rise to $12.3077 per share over the next 12 months.
-
What Do Analysts Say About Perspective Therapeutics, Inc.?
Analysts are divided on their view about Perspective Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.0000.
-
What Is Perspective Therapeutics, Inc.'s Price Target?
The price target for Perspective Therapeutics, Inc. over the next 1-year time period is forecast to be $12.3077 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CATX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Perspective Therapeutics, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CATX?
You can purchase shares of Perspective Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics, Inc. shares.
-
What Is The Perspective Therapeutics, Inc. Share Price Today?
Perspective Therapeutics, Inc. was last trading at $2.4000 per share. This represents the most recent stock quote for Perspective Therapeutics, Inc.. Yesterday, Perspective Therapeutics, Inc. closed at $2.3900 per share.
-
How To Buy Perspective Therapeutics, Inc. Stock Online?
In order to purchase Perspective Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CATX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CATX
Sector
P/E ratio
--
23.66x
PEG ratio
-0.04x
-0.01x
P/B ratio
0.73x
1.84x
Price / LTM sales
162.05x
1.60x
Growth Metrics
CATX
Sector
Revenue growth
-43.36%
4.85%
Earnings growth
-63.24%
11.15%
Revenue (5-year growth)
-27.61%
6.45%
Earnings forecast
-$0.32
-$0.20
Profitability
CATX
Sector
Profitability FY 2024
-$852K
$3.6M
Return on invested capital
-37.13%
-30.98%
Return on assets
-31.7%
-27.62%
Return on equity
-37.63%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
CATX
Sector
Total cash
$174.1M
$27.2M
Short term investments
$165.3M
$25.7M
Total assets
$350.1M
$79.9M
Long term debt
$2.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
